Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE

Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Blog
"The Hard Slog Will Continue:" Trends in Use and Spending on Medicines in the U.S.
Highlights from a webinar about the use and spending on medicines in 2022
Murray Aitken, Executive Director, IQVIA Institute for Human Data Science
Jun 20, 2022
  • Blogs
  • "The Hard Slog Will Continue:" Trends in Use and Spending on Medicines in the U.S.

The IQVIA Institute for Human Data Science hosted a webinar on May 10, 2022, which followed the publication of the Institute report, The Use of Medicines in the U.S. 2022. Usage and spending trends and outlook to 2026.

The webinar included participation from an esteemed group of panelists representing academic research, health economics, pharmaceuticals benefits managers, and the life sciences industry.

In the course of the webinar, panelists discussed a number of key topics:
  • The utilization of medicines and health system resilience: There was agreement among the panelists that the entire U.S. health system has demonstrated remarkable resilience during the pandemic. Unlike other business sectors – for example, semi-conductors – the entire pharmaceutical supply chain has held up well and avoided shortages that would have deprived patients of life-saving drugs. This is in large part due to the extraordinary collaboration among all players in the entire supply chain – manufacturers, pharmacy benefits managers, payers, providers, and others working well together. In general, the health system is almost back to pre-pandemic conditions while some disruptions are still lingering, with a cumulative backlog in parts of the care delivery chain. On the flipside, the pandemic has revealed serious challenges with the level of access to care for underserved populations, health disparities, and unresolved challenges such as antimicrobial resistance.
  • Heterogeneity in costs of drugs: The panelists concurred with the findings in the report that spending growth on medicines generally is slowing and that patient out-of-pocket costs on average are trending lower. However, the averages are obscuring the fact that categories of patients, in particular patients with chronic conditions such as cancer, immune disorders and HIV, can have significantly higher costs for their medicines. In certain therapeutic categories, especially those where specialty drugs have limited brand competition, costs can also be higher. In addition, uninsured patients face particular challenges. Overall, the level of heterogeneity across different patient populations, different therapeutic categories, and types of medicine is a big challenge both to understand and to address.
  • The rising role of the 340B Drug Pricing Program: The growth in 340B – the federal drug program that allows qualifying providers, hospitals and specialty clinics serving uninsured and low-income patients to purchase outpatient drugs from manufacturers at discounted prices – was described as resulting in it now being a larger program than Medicare Part D. The 340B program is controversial as studies have shown there is limited evidence that the resulting discounts are being used to reduce the costs of medicines to patients, and that instead cross-subsidization is leading to the savings being used to cover other expenses for hospitals and providers. This leads to distortions in the marketplace and consequences that are far from the original intent of the program.
  • Competition and specialty drugs: There were divergent opinions among the panelists whether there is sufficient competition, especially in the category of specialty medicines which now represent 56% of total drug spending. Some panelists found that competition still puts pressure on the costs of medicines, while others expressed concerns that competition is eroding. Even though there is general agreement in the health system that patients should have access to oncology drugs despite their high cost, patients don’t always get access to the medicines they need because payers demand pre-authorizations and stepped therapy, and price concessions by manufacturers in the form of rebates do not always flow to savings for the patient.
  • Cost-sharing and patient costs: Cost-sharing is an intentional part of insurance design overseen by formulary committees. Coupons are means to circumvent those approaches. However, the point was made that cost-sharing and the use of manufacturer coupons are band-aids on a larger affordability problem. While coupons may be the last resort for patients to get access to a drug, most patients would prefer to get proper access to a medication rather than use coupons.
  • Outlook for drug spending: There were general expectations among the panelists that net prices on medicines in general will continue to stay flat over the next year or so, even though prices on medicines for rare diseases, cancer, and immune disorders will continue to be at high levels. There was a call for smarter spending on medicines, not just more spending. It is also expected that there will be continued pressures to control costs of drugs, push the development of biosimilars, and reduce barriers for entry of generics. In the words of one of the panelists, “It will be a hard slog.”

The panelists represented different sectors of the U.S. pharmaceutical eco-system and research:

  • Kristin Bass, Chief Policy Officer, Pharmaceutical Care Management Association
  • Stacie Dusetzina, Ph.D., Associate Professor, Vanderbilt University
  • Richard G. Frank, Ph.D., Professor of Health Economics, Director – USC-Brookings  Schaeffer Initiative for Health Policy, Brookings Institution
  • Lori M. Reilly, JD, Chief Operating Officer, PhRMA

Join the conversation and hear how panelists responded to the topics above and more by viewing the webinar on-demand.

Contact Us